• Our Services
    • Care Navigation
    • Personalized Action Plans
    • The Cancer Commons Difference
    • Registering with Cancer Commons
    • Enhanced Services
    • Personal Tumor Boards
  • Education
    • Bladder Cancer
    • Brain Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Diffuse Midline Glioma
    • Esophageal Cancer
    • Kidney Cancer
    • Leukemia
    • Liver Cancer
    • Lung Cancer
    • Lymphoma
    • Melanoma
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Uterine Cancer
  • About Us
    • Our Story
    • Facing Advanced Cancer
    • Meet the Team that Cares
    • Our Core Values
    • Our Partners
    • Support Our Services
    • Talk to Us
    • Financial Documents
  • Testimonials
    • All Testimonials
  • Support Us
    • Donate Now
    • Many Ways to Give
    • What Your Support Makes Possible
  • Our Services
    • Care Navigation
    • Personalized Action Plans
    • The Cancer Commons Difference
    • Registering with Cancer Commons
    • Enhanced Services
    • Personal Tumor Boards
  • Education
    • Bladder Cancer
    • Brain Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Diffuse Midline Glioma
    • Esophageal Cancer
    • Kidney Cancer
    • Leukemia
    • Liver Cancer
    • Lung Cancer
    • Lymphoma
    • Melanoma
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Uterine Cancer
  • About Us
    • Our Story
    • Facing Advanced Cancer
    • Meet the Team that Cares
    • Our Core Values
    • Our Partners
    • Support Our Services
    • Talk to Us
    • Financial Documents
  • Testimonials
    • All Testimonials
  • Support Us
    • Donate Now
    • Many Ways to Give
    • What Your Support Makes Possible
 

New Approvals for Liver Cancer Mark ‘Golden Age’ of Treatment

July 28, 2021
Focus: Liver Cancer
Topics: Treatment Options

Reported in Healio: After decades of little or no progress, many new clinical trials testing targeted and immunotherapy drugs—especially in combinations—are showing that they have real value in treating primary liver cancer (hepatocellular carcinoma).

.

Tags: hepatocellular carcinoma, immunotherapy, lenvatinib, regorafenib, targeted therapy

Cancer Commons, a patient-centric nonprofit, features compassionate experts who build relationships with advanced cancer patients and caregivers to create personalized action plans. Our nurse navigators, PhD scientists, and national experts consult the latest, most-promising research to identify, explain, and help patients access their best-possible diagnostic and treatment options—so everyone feels confident they’ve left no stone unturned.

Don’t miss Cancer Commons Connects
Exclusive monthly insights and stories—from and for our community

Working.

Dealing with Cancer? Let Us Help

Our Services

  • Care Navigation
  • Personalized Action Plans
  • Registering with Cancer Commons
  • Enhanced Services
  • Personal Tumor Boards
  • Frequently Asked Questions (FAQ)

Perspectives

  • Latest Research
  • Treatment Options
  • Molecular Testing
  • Navigating Treatment
  • Living with Cancer
  • Patient Stories
  • Curious Dr. George
  • The Big Picture
  • Peer-Reviewed Publications

Organization

  • Our Story
  • Our Team
  • Our Core Values
  • Contact Us
  • Board of Directors
  • Partners
  • Expert Physician Advisors

About Us

  • News and Events
  • Contact Us
  • Financial Documents

Support & Giving

  • Contribute Now
  • Many Ways to Give
  • What Your Support Makes Possible
  • Testimonials


Donate

Cancer Commons
650 Castro Street, Suite 120-522
Mountain View, CA 94041, USA
650-289-4044

Patients Hotline

877-971-1200

  • Privacy Policy

© 2023 Cancer Commons.